---
title: Ferric Carboxymaltose in Heart Failure with Iron Deficiency
date: '2023-08-26'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/37632463/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&fc=20211015124055&ff=20230827181307&v=2.17.9.post6+86293ac
source: N Engl J Med
description: 'CONCLUSIONS: Among ambulatory patients who had heart failure with a
  reduced ejection fraction and iron deficiency, there was no apparent difference
  between ferric carboxymaltose and placebo with respect to the hierarchical composite
  of death, hospitalizations for heart failure, or 6-minute walk distance. (Funded
  by American Regent, a Daiichi Sankyo Group company; HEART-FID ClinicalTrials.gov
  number, ...'
disable_comments: true
---
CONCLUSIONS: Among ambulatory patients who had heart failure with a reduced ejection fraction and iron deficiency, there was no apparent difference between ferric carboxymaltose and placebo with respect to the hierarchical composite of death, hospitalizations for heart failure, or 6-minute walk distance. (Funded by American Regent, a Daiichi Sankyo Group company; HEART-FID ClinicalTrials.gov number, ...